- 1.7k Downloads
Ferric carboxymaltose (Ferinject®), a novel iron complex that consists of a ferric hydroxide core stabilized by a carbohydrate shell, allows for controlled delivery of iron to target tissues. Administered intravenously, it is effective in the treatment of iron-deficiency anaemia, delivering a replenishment dose of up to 1000 mg of iron during a minimum administration time of ≤15 minutes. Results of several randomized trials have shown that intravenously administered ferric carboxymaltose rapidly improves haemoglobin levels and replenishes depleted iron stores in various populations of patients with iron-deficiency anaemia, including those with inflammatory bowel disease, heavy uterine bleeding, postpartum irondeficiency anaemia or chronic kidney disease. It was well tolerated in clinical trials. Ferric carboxymaltose is, therefore, an effective option in the treatment of iron-deficiency anaemia in patients for whom oral iron preparations are ineffective or cannot be administered.
Ferric carboxymaltose is a macromolecular ferric hydroxide carbohydrate complex, which allows for controlled delivery of iron within the cells of the reticuloendothelial system and subsequent delivery to the iron-binding proteins ferritin and transferrin, with minimal risk of release of large amounts of ionic iron in the serum. Intravenous administration of ferric carboxymaltose results in transient elevations in serum iron, serum ferritin and transferrin saturation, and, ultimately, in the correction of haemoglobin levels and replenishment of depleted iron stores.
The total iron concentration in the serum increased rapidly in a dose-dependent manner after intravenous administration of ferric carboxymaltose. Ferric carboxymaltose is rapidly cleared from the circulation and is distributed primarily to the bone marrow (≈80%) and also to the liver and spleen. Repeated weekly administration of ferric carboxymaltose does not result in accumulation of transferrin iron in patients with iron-deficiency anaemia.
Intravenously administered ferric carboxymaltose was effective in the treatment of iron-deficiency anaemia in several 6- to 12-week, randomized, open-label, controlled, multicentre trials in various patient populations, including those with inflammatory bowel disease, heavy uterine bleeding or postpartum irondeficiency anaemia, and those with chronic kidney disease not undergoing or undergoing haemodialysis. In most trials, patients received either ferric carboxymaltose equivalent to an iron dose of ≤1000mg (or 15mg/kg in those weighing <66kg) administered over ≤15 minutes (subsequent doses administered at 1-week intervals) or oral ferrous sulfate at a dose equivalent to 65 mg iron three times daily or 100mg iron twice daily. In one trial, patients with chronic kidney disease undergoing haemodialysis received 200 mg of iron intravenously either as ferric carboxymaltose or iron sucrose administered into the haemodialysis line two to three times weekly. In all trials, ferric carboxymaltose was administered until each patient had received his or her calculated total iron replacement dose.
Haemoglobin-related outcomes improved in patients with iron-deficiency anaemia receiving ferric carboxymaltose. Treatment with ferric carboxymaltose was associated with rapid and sustained increases from baseline in haemoglobin levels. Ferric carboxymaltose was considered to be as least as effective as ferrous sulfate with regard to changes from baseline in haemoglobin levels or the proportion of patients achieving a haematopoietic response at various timepoints. In general, improvements in haemoglobin levels were more rapid with ferric carboxymaltose than with ferrous sulfate. In patients with chronic kidney disease undergoing haemodialysis, ferric carboxymaltose was at least as effective as iron sucrose.
Ferric carboxymaltose also replenished depleted iron stores and improved health-related quality-of-life (HR-QOL) in patients with iron-deficiency anaemia. Recipients of ferric carboxymaltose demonstrated improvements from baseline in serum ferritin levels and transferrin saturation, as well as improvements from baseline in HR-QOL assessment scores. Ferric carboxymaltose was at least as effective as ferrous sulfate with regard to endpoints related to serum ferritin levels, transferrin saturation and HR-QOL.
Ferric carboxymaltose was well tolerated in clinical trials in patients with irondeficiency anaemia, with most drug-related adverse events considered to be mild to moderate in severity. Commonly reported drug-related adverse events include headache, dizziness, nausea, abdominal pain, constipation, diarrhoea, rash and injection-site reactions.
The incidence of drug-related adverse events in patients receiving intravenous ferric carboxymaltose was generally similar to that in patients receiving oral ferrous sulfate. In general, rash and local injection-site reactions were more common with ferric carboxymaltose, whereas gastrointestinal adverse events were more frequent with ferrous sulfate. In patients with chronic kidney disease undergoing haemodialysis, a lower proportion of ferric carboxymaltose than iron sucrose recipients experienced at least one drug-related adverse event.
KeywordsChronic Kidney Disease Ferrous Sulfate Serum Ferritin Level Transferrin Saturation Intravenous Iron
- 1.World Health Organization. Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. Geneva: World Health Organization, 2001Google Scholar
- 2.de Benoist B, McLean E, Egli I, et al. Worldwide prevalence of anaemia 1993–2005: WHO Global Database. Geneva: World Health Organization, 2008Google Scholar
- 6.Dodd J, Dare M, Middleton P. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database Syst Rev 2004; (4): CD004222Google Scholar
- 10.National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults: using iron agents [online]. Available from URL: http://www.kidney.org/professionals/kdoqi/guidelines_anemia/cpr32.htm [Accessed 2009 Jan 22]
- 12.National Institute for Health and Clinical Excellence. Anaemia management in people with chronic kidney disease. NICE clinical guideline 39. London: National Institute for Health and Clinical Excellence, 2006 SepGoogle Scholar
- 16.UK Medicines and Healthcare Products Regulatory Agency. Public assessment report (decentralised procedure): Ferinject 50mg iron/ml solution for injection/infusion (PL 15240/0002; UK/H/0894/001/DC) [online]. Available from URL: http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con014025.pdf [Accessed 2008 Dec 9]
- 17.Ferinject: UK summary of product characteristics. Purley: Syner-Med (Pharmaceutical Products) Ltd, 2007 Jul 17Google Scholar
- 18.Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009; 23(1): 11–6Google Scholar
- 22.Geisser P, Banké-Bochita J. The pharmacokinetics, safety and tolerability of ferric carboxymaltose: data from a dose escalating study in patients with iron deficiency anaemia [abstract no. MP382 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; StockholmGoogle Scholar
- 24.Gordon SS, Hadley PE, Van Wyck DB, et al. Iron carboxymaltose, a new intravenous iron agent for iron deficiency anemia in heavy uterine bleeding [abstract]. Obstet Gynecol 2007 Apr; 109 (4 Suppl.): 108SGoogle Scholar
- 28.Qunibi WY, Martinez C, Smith M, et al. Efficacy and safety of IV ferric carboxymaltose (FCM) compared to oral iron in anemic patients with non-dialysis-dependent CKD [abstract no. MO017 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; StockholmGoogle Scholar
- 29.Schaefer RM, Khasabov NN, Todorov NG, et al. The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia [abstract no. MP375 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; StockholmGoogle Scholar
- 31.Toblli JE, Cao G, Oliveri L, et al. Evaluation of intravenous iron preparations on cardiovascular toxicity in normal rats [abstract no. PUB476]. American Society of Nephrology Renal Week; 2008 Nov 4–9; Philadelphia (PA)Google Scholar
- 33.Seid MH, Mangione A, Valaoras TG, et al. Safety profile of iron carboxymaltose, a new high dose intravenous iron in patients with iron deficiency anemia [abstract no. 3739]. Blood 2006 Nov 2; 108 (11 Pt 2): 8bGoogle Scholar
- 34.Qunibi W, Dinh Q, Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM): data from the FCM clinical program [abstract no. MP383 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; StockholmGoogle Scholar
- 35.Vifor Pharma. Overview of the safety of Ferinject (ferric carboxymaltose, FCM) in the clinical trial programme. St Gallen, Switzerland; Vifor (International), Inc., 2009 Jan 19 (Data on file)Google Scholar
- 36.Lu M. Injectafer® (iron carboxymaltose injection):NDA 22054: slide presentation [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4337s1-05-FDA-Lu.ppt [Accessed 2008 Dec 11]
- 37.Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Drug Safety and Risk Management Advisory Committee, February 1, 2008 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4337m1-Final.pdf [Accessed 2008 Dec 11]
- 38.US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 16]
- 40.Grimmelt A-C, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009 Feb; 71(2): 125–9Google Scholar
- 41.European Medicines Agency. CosmoFer: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=14139 [Accessed 2009 Jan 21]
- 42.European Medicines Agency. Venofer 20 mg/ml solution for injection: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=14438 [Accessed 2009 Jan 21]
- 43.Ferrlecit® (sodium ferric gluconate complex in sucrose injection): US product monograph. Corona (CA): Watson Pharma, Inc., 2003 Apr 13Google Scholar